1598426-03-9

Basic information

• Product Name: 2-(1-Phenyl-cyclopropylamino)-pyrimidine-5-carboxylic acid ethyl ester
• Synonyms: 2-(1-Phenyl-cyclopropylamino)-pyrimidine-5-carboxylic acid ethyl ester;CTTSUGRYXUPYIO-UHFFFAOYSA-N
• CAS NO: 1598426-03-9
• Molecular Formula: C16H17N3O2
• Molecular Weight: 283.32508
• Mol File: 1598426-03-9.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 457.2±47.0 °C(Predicted)
• Appearance: /
• Density: 1.278±0.06 g/cm3(Predicted)
• PKA: 1.94±0.10(Predicted)
• CAS DataBase Reference: 2-(1-Phenyl-cyclopropylamino)-pyrimidine-5-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-Phenyl-cyclopropylamino)-pyrimidine-5-carboxylic acid ethyl ester(1598426-03-9)
• EPA Substance Registry System: 2-(1-Phenyl-cyclopropylamino)-pyrimidine-5-carboxylic acid ethyl ester(1598426-03-9)

Safety Data

• Hazardous Substances Data: 1598426-03-9(Hazardous Substances Data)

Usage

General Description

2-(1-Phenyl-cyclopropylamino)-pyrimidine-5-carboxylic acid ethyl ester is a chemical compound with the molecular formula C18H18N4O2. It is an ethyl ester derivative of a pyrimidine carboxylic acid with a phenyl-cyclopropylamino group attached to the pyrimidine ring. 2-(1-Phenyl-cyclopropylamino)-pyrimidine-5-carboxylic acid ethyl ester has potential pharmaceutical applications, potentially functioning as a drug or drug intermediate. It may also have uses in organic synthesis or as a research tool in the study of pyrimidine derivatives. The specific properties and uses of this compound would need to be further investigated through research and testing.

Upstream product

• 89793-12-4 ethyl 2-chloropyrimidine-5-carboxylate 
• 41049-53-0 1-phenylcyclopropylamine 
• 100-47-0 benzonitrile 
• 73930-39-9 1-phenylcyclopropane-1-amine hydrochloride 

Downstream Products

• 1375465-91-0 N-hydroxy-2-((1-phenylcyclopropyl)amino)pyrimidine-5-carboxamide 

Relevant articles and documents

METALLOENZYME INHIBITOR COMPOUNDS

Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.

INCREASING EXPRESSION OF INTERFERON REGULATED GENES WITH COMBINATONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS

Provided herein is a combination comprising an HDAC inhibitor and an IMiD for increasing interferon regulated gene expression or decreasing c-MYC gene expression in a cancer cell or tumor in a subject in need thereof. Increasing interferon regulated gene expression may result in increased recognition of tumors by innate or adaptive immune system and an increase in programmed cell death (apoptosis) gene expression, increasing apoptosis in cancer cells and tumors. The cells can be multiple myeloma cells or diffuse large B-cell lymphoma cells. Also provided are methods for treating myelodysplastic syndromes/acute myeloid leukemia (MDS/AML) or pathogen infections in a subject in need thereof comprising administering to the subject an effective amount of HDAC inhibitor and an IMiD. The HDAC inhibitor can be an HDAC6-selective inhibitor.

METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HDAC INHIBITORS WITH BET INHIBITORS

The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a BET inhibitor for the treatment of cancer in a subject in need thereof. Also provided herein are methods for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a BET inhibitor.